Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide, Methotrexate, and Rituximab with Radiation for PCNSL
NCT00068250Phase 2Completed
- Sponsor
- NRG Oncology
- Start
- Jul 2003
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide in primary central nervous system lymphoma (PCNSL) (4 arms), sponsored by NRG Oncology. Primary endpoints: Maximum Tolerated Dose at 15 weeks and Overall Survival Rate at 2 years. Started Jul 2003; status: completed.
02
Drugs
temozolomide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00068250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068250.